肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

葛兰素史克牵手Immunocore研发抗癌新药

2013-07-10 大智慧 大智慧

抗癌新药FDA
关注

据路透社周二报道，英国最大的医药集团葛兰素史克将与生物科技公司Immunocore共同研发新一代抗癌药物，该药的治疗效果优于其他以抗体为基础的抗癌药。 Immunocore的核心科技是被其称为“ImmTACs”的药物。据了解，ImmTACs借用T细胞受体来识别癌症或滤过性病毒感染过程中细胞出现的变化，之后该药物能有效激活免疫系统将相关感染细胞消灭。 葛兰素史克两位合伙人于周二表示说，公司会预先

据路透社周二报道，英国最大的医药集团葛兰素史克将与生物科技公司Immunocore共同研发新一代抗癌药物，该药的治疗效果优于其他以抗体为基础的抗癌药。

Immunocore的核心科技是被其称为“ImmTACs”的药物。据了解，ImmTACs借用T细胞受体来识别癌症或滤过性病毒感染过程中细胞出现的变化，之后该药物能有效激活免疫系统将相关感染细胞消灭。

葛兰素史克两位合伙人于周二表示说，公司会预先支付Immunocore公司1.42亿英镑的临床前授权金。等到该药正式上市之后，Immunocore还能获得2亿英镑的收入，另外该公司还能获得2位数的销售提成。

传统的癌症治疗手段只能识别细胞表层变化，葛兰素史克生物医药研发和创新总监劳伦特·杰斯佩表示说，ImmTACs的出现将会是癌症治疗领域的一个重大突破。（生物谷Bioon.com）

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651184, encodeId=9e0e165118498, content=<a href='/topic/show?id=1e61555223e' target=_blank style='color:#2F92EE;'>#抗癌新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55522, encryptionId=1e61555223e, topicName=抗癌新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6224143528, createdName=zhangmingxiang, createdTime=Tue Mar 18 03:08:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299746, encodeId=9a801299e4682, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315721, encodeId=c48f1315e2100, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561979, encodeId=857215619e976, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2014-03-18 zhangmingxiang

    #抗癌新药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1651184, encodeId=9e0e165118498, content=<a href='/topic/show?id=1e61555223e' target=_blank style='color:#2F92EE;'>#抗癌新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55522, encryptionId=1e61555223e, topicName=抗癌新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6224143528, createdName=zhangmingxiang, createdTime=Tue Mar 18 03:08:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299746, encodeId=9a801299e4682, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315721, encodeId=c48f1315e2100, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561979, encodeId=857215619e976, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-07-12 lqvr

    #研发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1651184, encodeId=9e0e165118498, content=<a href='/topic/show?id=1e61555223e' target=_blank style='color:#2F92EE;'>#抗癌新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55522, encryptionId=1e61555223e, topicName=抗癌新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6224143528, createdName=zhangmingxiang, createdTime=Tue Mar 18 03:08:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299746, encodeId=9a801299e4682, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315721, encodeId=c48f1315e2100, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561979, encodeId=857215619e976, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-07-12 sjq027

    #葛兰素史克#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1651184, encodeId=9e0e165118498, content=<a href='/topic/show?id=1e61555223e' target=_blank style='color:#2F92EE;'>#抗癌新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55522, encryptionId=1e61555223e, topicName=抗癌新药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6224143528, createdName=zhangmingxiang, createdTime=Tue Mar 18 03:08:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299746, encodeId=9a801299e4682, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315721, encodeId=c48f1315e2100, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561979, encodeId=857215619e976, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Jul 12 08:08:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-07-12 docwu2019

    #CORE#

    0